MARKET

AGEN

AGEN

Agenus
NASDAQ
3.510
-0.080
-2.23%
After Hours: 3.540 +0.03 +0.85% 17:47 12/18 EST
OPEN
3.600
PREV CLOSE
3.590
HIGH
3.721
LOW
3.510
VOLUME
338.92K
TURNOVER
--
52 WEEK HIGH
7.34
52 WEEK LOW
1.380
MARKET CAP
119.37M
P/E (TTM)
-1.6780
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AGEN last week (1208-1212)?
Weekly Report · 3d ago
GSK gets EU backing to market Arexvy RSV shot for all adults
Seeking Alpha · 6d ago
Weekly Report: what happened at AGEN last week (1201-1205)?
Weekly Report · 12/08 10:41
Weekly Report: what happened at AGEN last week (1124-1128)?
Weekly Report · 12/01 10:35
Weekly Report: what happened at AGEN last week (1117-1121)?
Weekly Report · 11/24 10:41
Agenus Inc. Hosts Stakeholder Webcast Showcasing BOT/BAL Progress and GI Oncology Advances
Reuters · 11/19 21:01
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
Barchart · 11/19 15:01
Agenus appoints Jose Iglesias as chief medical affairs officer
TipRanks · 11/18 14:36
More
About AGEN
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.